Evolent Health, Inc. (NYSE:EVH) Shares Sold by Truist Financial Corp

Truist Financial Corp trimmed its holdings in Evolent Health, Inc. (NYSE:EVH) by 4.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 79,268 shares of the technology company’s stock after selling 3,733 shares during the quarter. Truist Financial Corp owned approximately 0.07% of Evolent Health worth $1,516,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Chicago Partners Investment Group LLC purchased a new stake in Evolent Health during the 4th quarter valued at approximately $228,000. Wellington Management Group LLP lifted its holdings in shares of Evolent Health by 96.1% during the fourth quarter. Wellington Management Group LLP now owns 8,313,157 shares of the technology company’s stock worth $274,584,000 after purchasing an additional 4,073,959 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Evolent Health by 2.1% during the fourth quarter. Vanguard Group Inc. now owns 10,821,331 shares of the technology company’s stock worth $357,429,000 after purchasing an additional 226,691 shares during the period. NBC Securities Inc. grew its position in Evolent Health by 16.6% in the 1st quarter. NBC Securities Inc. now owns 2,461 shares of the technology company’s stock valued at $81,000 after buying an additional 350 shares during the last quarter. Finally, Banque Cantonale Vaudoise acquired a new position in Evolent Health in the 1st quarter valued at $88,000.

Evolent Health Stock Performance

NYSE:EVH opened at $27.06 on Friday. The company has a current ratio of 1.08, a quick ratio of 1.08 and a debt-to-equity ratio of 0.57. The company has a market capitalization of $3.14 billion, a P/E ratio of -21.65 and a beta of 1.56. The firm has a 50-day moving average price of $28.41 and a two-hundred day moving average price of $25.82. Evolent Health, Inc. has a twelve month low of $17.98 and a twelve month high of $35.00.

Evolent Health (NYSE:EVH) last issued its quarterly earnings data on Thursday, August 8th. The technology company reported $0.30 earnings per share for the quarter, topping analysts’ consensus estimates of $0.21 by $0.09. Evolent Health had a negative net margin of 3.16% and a positive return on equity of 8.47%. The business had revenue of $647.10 million during the quarter, compared to analysts’ expectations of $636.46 million. During the same period last year, the company posted $0.06 EPS. The company’s revenue was up 37.9% on a year-over-year basis. As a group, research analysts expect that Evolent Health, Inc. will post 0.86 earnings per share for the current fiscal year.

Analysts Set New Price Targets

EVH has been the topic of several analyst reports. Stephens reaffirmed an “overweight” rating and issued a $42.00 target price on shares of Evolent Health in a report on Tuesday, July 30th. Truist Financial reiterated a “buy” rating and set a $33.00 target price on shares of Evolent Health in a research report on Tuesday, August 27th. JMP Securities reduced their price target on Evolent Health from $34.00 to $31.00 and set a “market outperform” rating for the company in a report on Friday, August 9th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $42.00 price objective on shares of Evolent Health in a report on Tuesday, October 8th. Finally, KeyCorp started coverage on Evolent Health in a report on Friday. They issued an “overweight” rating and a $35.00 target price for the company. One analyst has rated the stock with a sell rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $39.91.

Insider Activity

In related news, COO Emily Ann Rafferty sold 8,861 shares of the business’s stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $30.00, for a total value of $265,830.00. Following the completion of the transaction, the chief operating officer now owns 63,408 shares of the company’s stock, valued at approximately $1,902,240. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Evolent Health news, COO Emily Ann Rafferty sold 8,861 shares of Evolent Health stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $30.00, for a total value of $265,830.00. Following the completion of the sale, the chief operating officer now directly owns 63,408 shares of the company’s stock, valued at approximately $1,902,240. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, President Daniel Joseph Mccarthy sold 23,693 shares of the business’s stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $30.89, for a total value of $731,876.77. Following the completion of the transaction, the president now owns 198,809 shares of the company’s stock, valued at $6,141,210.01. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 307,291 shares of company stock worth $9,290,385 over the last three months. 1.60% of the stock is currently owned by corporate insiders.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.